# A GHK-Cu serum cut wrinkle volume more than plain serum

URL: https://sciencebased.news/ghk-cu/
Published: 2026-10-16  Updated: 2026-10-23
Claim: A GHK-Cu copper peptide serum smooths wrinkles. Grade: Promising

What to do:
- Apply a GHK-Cu serum to clean skin twice a day, morning and evening, for at least 8 weeks before you judge it.
- Expect a modest change. In the best trial, wrinkle volume fell 24% with the copper serum and 15% with the same serum without it.
- Pick a product with a delivery system. GHK-Cu barely gets through skin on its own, and the trial serum used tiny fat-based carriers.
- Safety: one person in 40 had mild redness. After microneedling, 8 of 20 people who used copper serum got dark patches, against none without it.
- Not proven: that GHK-Cu regrows hair, heals wounds, resets your genes or does anything by injection. No trial in people shows it.


# A GHK-Cu serum cut wrinkle volume more than plain serum

*Evidence check, October 16, 2026. Updated October 23, 2026.*

> **The claim:** "A GHK-Cu copper peptide serum smooths wrinkles."
>
> **Our grade: Promising.** In one well-run trial of 40 women, a copper peptide serum shrank wrinkles more than the same serum without it, and more than a popular peptide cream. It has not been repeated, and it was paid for by the serum's maker. Claims for hair, wounds, injections and genes rest on far less.

![A woman in her late 30s touches the corner of her eye with two fingers and holds a small amber dropper bottle labeled GHK-Cu](https://sciencebased.news/images/ghk-cu-hero-2.jpg)

You are 38, the lines at the corners of your eyes stay put after you stop smiling, and your feed is full of blue serums called copper peptides.

Is the blue bottle worth it?

For wrinkles, there is a real trial behind it. In 2016, 40 women aged 40 to 65 put a GHK-Cu serum on one side of the face and a serum without it on the other, twice a day for 8 weeks [1]. The copper side came out ahead.

That is odd, for two reasons. GHK-Cu barely gets through skin. And the same molecule, sold as a wound gel in the 1990s, flopped in a big trial. So what did this serum do differently, and how much of the gain was the copper?


## Where the claim came from

GHK is a tiny protein, just three amino acids, that grabs copper. Loren Pickart found it more than 40 years ago while comparing blood from people aged 20 to 25 with blood from people aged 50 to 70. The young blood worked better on liver tissue in a dish, and the active ingredient turned out to be GHK. Its level falls with age [2]. GHK-Cu is GHK carrying its copper.

Pickart's company, ProCyte, turned it into a wound gel in the 1990s. When that failed (more below), copper peptides moved into face creams. They are now back in the spotlight as a longevity peptide. On his podcast in April 2026, Ben Greenfield called GHK-Cu "one of the most well researched hair peptides" and described using it after microneedling, which means pricking the skin with fine needles [3]. In September, NPR reported that people are now injecting it, "ahead of the science" [4].

So which of these claims has a trial in people? The face cream is the strongest.

## The wrinkle trial

The first clue is in how the serum was made. The study comes from the University of Auckland in New Zealand. GHK-Cu loves water, so it barely gets through the fatty outer layer of skin. The team packed it into tiny fat-based carriers to help it in [1].

An independent German testing lab, Dermatest, ran the trial. It was randomized and double-blind, and it used a split face: each woman was her own control. One group of 20 put the copper serum on one side and the same serum without the copper or the carriers on the other. A second group of 19 put the copper serum on one side and Strivectin SD Advanced on the other, a store cream built on Matrixyl 3000, another popular skin peptide. A 3D skin camera measured one wrinkle at the corner of the eye before and after.

![Bar chart of the change in wrinkle volume at the corner of the eye after 8 weeks of twice-daily serum. First comparison, 20 women: GHK-Cu serum minus 24.1%, plain serum minus 15.0%. Second comparison, 19 women: GHK-Cu serum minus 25.8%, Matrixyl cream minus 20.0%.](https://sciencebased.news/images/ghk-cu-chart.png)

After 8 weeks, wrinkle volume fell 24.1% on the copper side and 15.0% on the plain side. Against the Matrixyl cream it was 25.8% against 20.0%. Both gaps were large enough to rule out chance [1]. Wrinkle depth fell 20.3% against 15.3% compared with plain serum. Against Matrixyl the depth gap was smaller and could have been chance.

Now look at the plain side. It shrank wrinkles too, by 15%, with no copper at all. The paper calls the copper result a 55.8% bigger drop than the plain serum, and that is right as math: 24.1 is about 1.6 times 15.0. In plain terms, the copper did about 9 points more than a good moisturizer. That is the answer to how much.

In the same paper, skin cells grown with GHK-Cu made about 30% more elastin, the protein that lets skin snap back [1]. That fits the result, but cells are not faces.

## What the failures tell you

One trial is one trial. GHK-Cu has looked good in a small study before and then let people down.

The wound gel looked like a breakthrough first. In a 1994 trial of people with diabetic foot ulcers, ProCyte's GHK-Cu gel, Iamin, closed plantar ulcers (on the sole) by a median of 98.5%, against 60.8% on a gel without it. Infections were 7% against 34% [5]. That trial was randomized and the people judging the wounds did not know who got what. It had 181 people, but the 98.5% came from the 60 with sole ulcers who started right away. People who used the plain gel for 4 weeks before switching to Iamin did no better than plain gel.

Then came the big repeat. In October 1994, ProCyte reported that in 511 people at 30 medical centers, Iamin worked no better than placebo. Its stock fell as much as 75% in a day [6]. An analyst said the gel did as well as before; the placebo simply did much better.

Leg ulcers went the same way. In a 4-week trial of 86 people with venous ulcers, ulcers shrank 18.7% with a copper tripeptide cream, 22.5% with placebo and 44% with a standard silver cream [7].

After laser resurfacing around the mouth, 13 patients were split into two groups for 12 weeks: 7 used copper peptide products and 6 used ordinary ones. Blinded doctors and computer scans found no difference in redness or wrinkles. The copper group rated their results higher, but they got more free products and more time with the doctor, and they knew what they were using [8].

In 2025, Indian dermatologists treated 40 people with acne scars by microneedling alone or microneedling plus a 1% GHK-Cu serum, five sessions over 12 weeks. The groups were not randomized, and they differed at the start. The copper group looked better at first, but from week 6 on there was no difference. Eight of the 20 people in the copper group got dark patches (hyperpigmentation); none did with the needles alone [9].

So outside the wrinkle trial, GHK-Cu has a pattern: a promising small start, then no edge in the larger or better-blinded test [5, 6, 7, 8, 9]. A 2026 systematic review called the human evidence "thin and fragmented" [10].

## The bigger claims

The longevity buzz rests mostly on a 2014 paper by Pickart and two colleagues. It said GHK changed the activity of about a third of human genes by 50% or more [2]. Those numbers come from a public database of drug effects measured in two lines of cancer cells grown in a dish. No one gave GHK to a person and measured their genes.

A 2012 study from Boston University is more careful. It found a gene pattern tied to lung damage in emphysema, then searched the same database for drugs that reverse it. GHK came out on top, and in the lab it helped lung cells from people with lung disease rebuild their tissue [11]. That is a good lead for a drug. It is not a trial.

In mice, a 2026 preprint (not yet checked by other scientists) gave GHK-Cu to 20-month-old mice, which is old for a mouse. Those that got it through the nose for 8 weeks found the exit of a maze faster, in both sexes. Injections into the belly for 5 days helped only males, and only briefly [12].

No study has given injected GHK-Cu to people. The FDA warns that injected GHK-Cu "may pose risk for immunogenicity," meaning an immune reaction, from clumping and impurities, and that there are "limited data in humans" on safety [13]. In May 2026 the agency allowed pharmacies to compound it again for use on the skin, but not for injection [14].

So back to the blue bottle. The one thing GHK-Cu has done well in a fair test in people is the thing it is sold for in that bottle: smoothing wrinkles a bit more than a plain serum.

## Our grade

The story so far is one good wrinkle trial against a run of misses elsewhere. Here are the five studies that matter most, rated one by one, so you can see which claims stand on a trial in people.

| Study | Evidence | Grade |
|---|---|---|
| Wrinkles: Badenhorst 2016 [1] | 40 women, randomized, double-blind, split face, 8 weeks. Volume down 24% against 15% for plain serum. Maker-funded, not repeated | Promising |
| Diabetic foot ulcers: Mulder 1994, then the phase 3 [5, 6] | 181 people: 98.5% against 60.8% closure of sole ulcers. Repeat in 511 people: no better than placebo | Debunked |
| Leg ulcers: Bishop 1992 [7] | 86 people, randomized: no better than placebo | Debunked |
| Acne scars with microneedling: 2025 [9] | 40 people, not randomized: no difference from week 6; dark patches in 8 of 20 | Weak |
| Genes and aging: Pickart 2014, Campbell 2012 [2, 11] | Gene data from cells in a dish; no person given GHK-Cu | Unproven |
| Overall: a GHK-Cu serum smooths wrinkles | One good trial for, none against | Promising |

The case for the other side: the wrinkle trial was paid for by Snowberry, the New Zealand company that made the serum, with a government grant [1]. It measured one wrinkle per person, and the paper does not say how much GHK-Cu was in the serum. It was published in a small journal and no other team has repeated it.

The plain serum also did a lot. It cut wrinkle volume by 15% by itself, so most of what you see in the mirror may be the moisturizer, not the copper.

What would change the grade: a second trial by a different team, with the dose stated, would move wrinkles toward Solid. A placebo trial of hair growth, or of injections, would give those claims a grade. A phase 2 trial of a GHK-Cu gel on fresh skin wounds, from Hudson Biotech, began enrolling 60 people in February 2026 [15].

## What this means for you

- If you want a copper peptide serum for fine lines, use it twice a day for 8 weeks before you judge it. That is what the trial did [1].
- Expect a modest gain over a good moisturizer: about 9 points more in wrinkle volume, at one spot.
- Look for a product that says how it gets the peptide into skin. GHK-Cu on its own barely passes the skin barrier [1].
- Be careful with microneedling plus copper serum, especially if you tan easily or have darker skin. In the acne-scar study, 8 of the 20 people in the copper group got dark patches [9].
- Do not inject it. No study has tested injected GHK-Cu in people, and the FDA flags an immune risk [13].
- For hair, wounds or aging inside the body, there is no human trial to go on yet.



## What's next

Hudson Biotech's trial of a GHK-Cu gel on fresh skin wounds, with about 60 people, is recruiting [15]. The FDA's advisers are due to discuss compounded GHK-Cu by February 2027 [14]. We will update this article when either reports.

This is the eighth of our one-by-one checks on the peptides in [our guide to the best peptides](/peptide-guide/), after [TB-500](/tb-500/), [AOD-9604](/aod-9604/) and [MK-677](/mk-677/). Our [peptides article](/peptides/) covers BPC-157. The ninth is [melanotan II](/melanotan-ii/), the tanning peptide.

## Sources

1. Badenhorst T, Svirskis D, Merrilees M, Bolke L, Wu Z. Effects of GHK-Cu on MMP and TIMP expression, collagen and elastin production, and facial wrinkle parameters. *Journal of Aging Science*, 2016. 40 women aged 40-65, randomized, double-blind, split-face, 8 weeks (39 finished); funded by Snowberry New Zealand, which made the serum, and Callaghan Innovation. [doi:10.4172/2329-8847.1000166](https://doi.org/10.4172/2329-8847.1000166)
2. Pickart L, Vasquez-Soltero JM, Margolina A. GHK and DNA: resetting the human genome to health. *BioMed Research International*, 2014. Analysis of gene data from cancer cell lines; first author discovered GHK. [doi:10.1155/2014/151479](https://doi.org/10.1155/2014/151479)
3. Greenfield B. Solo episode #499. *Ben Greenfield Life* podcast, April 18, 2026. https://bengreenfieldlife.com/podcast/solo-episode-499
4. NPR. People are injecting copper peptides ahead of the science. September 7, 2026. https://www.npr.org/2026/09/07/nx-s1-5955552/copper-peptides-skin-aging-health-safe
5. Mulder GD, Patt LM, Sanders L, et al. Enhanced healing of ulcers in patients with diabetes by topical treatment with glycyl-l-histidyl-l-lysine copper. *Wound Repair and Regeneration*, 1994. 181 people with diabetic foot ulcers, randomized, evaluator-blinded, up to 8 weeks of treatment plus 6 weeks of follow-up; the 98.5% result is from the 60 with sole ulcers treated from the start; company-run (ProCyte). [doi:10.1046/j.1524-475X.1994.20406.x](https://doi.org/10.1046/j.1524-475X.1994.20406.x)
6. Procyte drug fails test; stock plunges. *The Seattle Times*, October 17, 1994. Phase 3 of Iamin gel, 511 people at 30 centers. https://archive.seattletimes.com/archive/19941017/1936453/procyte-drug-fails-test-stock-plunges----clinical-trials-cast-doubt-on-companys-future
7. Bishop JB, Phillips LG, Mustoe TA, et al. A prospective randomized evaluator-blinded trial of two potential wound healing agents for the treatment of venous stasis ulcers. *Journal of Vascular Surgery*, 1992. 93 people randomized, 86 analyzed, evaluator-blinded, 4 weeks; funded by Schering-Plough, peptide supplied by ProCyte. [doi:10.1067/mva.1992.37086](https://doi.org/10.1067/mva.1992.37086)
8. Miller TR, Wagner JD, Baack BR, Eisbach KJ. Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin. *Archives of Facial Plastic Surgery*, 2006. 13 patients randomized into two groups (7 used ProCyte GHK-Cu products, given free and open label; 6 used standard products), 12 weeks. [doi:10.1001/archfaci.8.4.252](https://doi.org/10.1001/archfaci.8.4.252)
9. Vignesh NR, Balakumaran C, Ashok Kumar N, Sukanya G, Sakthi Megalai A, Sowbaghya PT. A study comparing the effect of dermaroller versus dermaroller with copper peptide in the management of acne scars. *Journal of Cutaneous and Aesthetic Surgery*, 2025. 40 people, not randomized, 12 weeks plus follow-up to week 16; no funding. [doi:10.25259/JCAS_56_2025](https://doi.org/10.25259/JCAS_56_2025)
10. Najafi N, Maatouk H, Vardanyan KG, Vartanian KB, Agrawal DK. A systematic review of the mechanisms and therapeutic applications of GHK-Cu. *Archives of Internal Medicine Research*, 2026. Review. [doi:10.26502/aimr.0255](https://doi.org/10.26502/aimr.0255)
11. Campbell JD, McDonough JE, Zeskind JE, et al. A gene expression signature of emphysema-related lung destruction and its reversal by the tripeptide GHK. *Genome Medicine*, 2012. Lung tissue gene data and lab cells. [doi:10.1186/gm367](https://doi.org/10.1186/gm367)
12. Mazzola J, Rosenfeld M, Tucker M, Wezeman J, Ladiges W, Liao G. Middle-aged mice treated with GHK-Cu peptide administered intraperitoneally or intranasally show behavioral rescue but divergent hippocampal aging programs. *Research Square* preprint, 2026. 100 mice; funded by the National Institute on Aging. [doi:10.21203/rs.3.rs-9520102/v1](https://doi.org/10.21203/rs.3.rs-9520102/v1)
13. US Food and Drug Administration. Certain bulk drug substances for use in compounding that may present significant safety risks (GHK-Cu, injectable). https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
14. US Food and Drug Administration. Bulk drug substances nominated for use in compounding under section 503A, updated May 14, 2026: GHK-Cu (except for injectable routes) in category 1. https://www.fda.gov/media/94155/download
15. Hudson Biotech. Topical GHK-Cu gel for acute skin wound healing. ClinicalTrials.gov NCT07437586, phase 2, about 60 people, recruiting since February 2026. https://clinicaltrials.gov/study/NCT07437586